FUNDING OF EXUBERA

Motion Text

That this House notes the interim recommendation made by the National Institute for Health and Clinical Excellence (NICE) not to fund the drug Exubera; believes that inhaled insulin would greatly improve the quality of life for the two million diabetics in the UK who are often forced to inject up to five times a day; further notes that this is the first major breakthrough in the treatment of diabetes since the discovery of insulin in the 1920s; urges the Government and NICE to reconsider its decision; encourages all interested parties to make representations to NICE by 10th May to urge them to reconsider their stance; and hopes that NICE will listen to the growing number of people and organisations who want this inhaled insulin to be freely available.